Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

One day after he was named the director of the FDA’s Center for Biologics Evaluation and Research, Vinay Prasad showed up at ...

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...

FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...

What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public ...

Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a most favored nation plan to reduce drug prices, President Donald Trump is ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.